Windtree Therapeutics (WINT) investor relations material

Company overview and business model

• Operates as a diversified biotech and pharmaceutical company, focusing on partnerships, manufacturing, and acquisitions of small companies with FDA-approved products.

• Became manufacturing sourcing agent for Evofem's Phexxi® in March 2025 and signed a manufacturing deal with Zhaoke (Hong Kong) in June 2025.

• Launched a new strategy in January 2025 to become a revenue-generating biotech through acquisitions and strategic subsidiaries.

• Lead product candidate istaroxime targets cardiogenic shock and acute heart failure; additional pipeline includes SERCA2a activators, rostafuroxin for hypertension, and aPKCi inhibitors for oncology.

• Engages in licensing and partnership agreements, notably with Lee's Pharmaceutical (HK) Ltd. for Greater China.

Financial performance and metrics

• Accumulated deficit of $861.3 million as of June 30, 2025; net loss of $10.6 million for Q2 2025.

• Operating losses of $26.1 million in 2024 and $20.6 million in 2023.

• Cash and cash equivalents of $301,000 and current liabilities of $15.7 million as of June 30, 2025.

• Auditor's opinion includes substantial doubt about ability to continue as a going concern.

• Financing primarily through equity offerings, convertible notes, and private placements.

Use of proceeds and capital allocation

• May receive up to $50 million in gross proceeds from Seven Knots under the ELOC Purchase Agreement; proceeds intended for working capital and general corporate purposes.

• At least 30% of net proceeds from VWAP Purchases under the ELOC must be used to repay indebtedness, then to redeem preferred stock, with the balance for a Binance Coin Treasury Initiative.

• No proceeds from the resale of shares by selling stockholders.